Blinatumomab: Phase II started

Micromet began the single-arm, international, pivotal Phase II BLAST trial to evaluate daily 15 µg/m 2 IV blinatumomab for the first 28 days of a 6-week cycle for up to 4 cycles in 130 precursor B cel...